Physician profile
James C Kearse
NPI 1013969245
$4,047.71
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $1,326 · 2021: $1,434 · 2022: $25.43 · 2023: $12.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.20 | 2019-2021 | |
| Amgen INC. | $358.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.60 | 2019-2021 | |
| Novo Nordisk INC | $257.58 | 2019-2021 | |
| Amarin Pharma, INC. | $254.60 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.63 | 2019-2021 | |
| Astellas Pharma US INC | $248.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $211.59 | 2019-2022 | |
| Abbvie INC. | $163.11 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $162.10 | 2019-2021 | |
| Pfizer INC. | $157.08 | 2019-2021 | |
| Zyla Life Sciences, INC. | $124.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.20 | 2019-2021 | |
| Eisai INC. | $95.20 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.23 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $81.66 | 2020-2021 | |
| Lilly USA, LLC | $75.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.67 | 2019-2021 | |
| Esperion Therapeutics, INC. | $51.73 | 2020-2021 | |
| Optinose US, INC. | $41.82 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.63 | 2020-2021 | |
| Sanofi Pasteur INC. | $39.98 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $34.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $32.64 | 2021 | |
| Allergan, INC. | $28.22 | 2020 | |
| Insmed, INC. | $28.12 | 2019-2021 | |
| Aytu Biopharma, INC. | $21.29 | 2019 | |
| Seqirus USA INC | $19.08 | 2019 | |
| Shionogi INC | $15.25 | 2019 | |
| Acadia Pharmaceuticals INC | $14.28 | 2021 | |
| Alfasigma USA, INC. | $14.23 | 2021 | |
| Dexcom, INC. | $13.92 | 2021 | |
| Medtronic Minimed, INC. | $13.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.31 | 2019 | |
| Pulmonx Corporation | $13.13 | 2020 | |
| Mylan Specialty L.P. | $12.96 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.90 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kearse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.